Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gratisovir and Ribavirin in Egyptian pediatric patients with chronic hepatitis C
NCT02985281Phase 3Unknown
- Sponsor
- National Liver Institute
- Start
- Dec 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sofosbuvir in hepatitis C (HCV) (2 arms), sponsored by National Liver Institute. Primary endpoint: Sustained Virological Response at 12 weeks post-treatment. Status: unknown.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02985281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985281.